Pfizer Announces Acquisition of Metsera in $4.9 Billion Deal to Expand Obesity Treatment Portfolio
I'm PortAI, I can summarize articles.
Pfizer Inc. has announced its acquisition of Metsera for $4.9 billion, paying $47.50 per share in cash. The deal includes a contingent value right that could yield additional payments of up to $22.50 per share based on clinical and regulatory milestones. The transaction is expected to close in Q4 2025, subject to regulatory approvals. Citi is Pfizer's financial advisor, while Metsera's advisors include Goldman Sachs and Guggenheim Securities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments